Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Sarah B. Goldberg"'
Autor:
Ryan J. Hartmaier, Aleksandra Markovets, Byoung Chul Cho, Adrianus J. de Langen, Sarah B. Goldberg, Jonathan Goldman, Xiuning Le, Isamu Okamoto, Jonathan W. Riess, Jan Cosaert, Helena Yu, Zofia Piotrowska
Publikováno v:
Cancer Research. 82:LB078-LB078
Background/Purpose: Osimertinib, a third-generation, irreversible, EGFR tyrosine kinase inhibitor (TKI), is the preferred 1L treatment for pts with EGFRm NSCLC. Unfortunately, most of these pts will eventually develop treatment resistance. ORCHARD is
Autor:
Philip Brohawn, Niels Reinmuth, Paul Baas, David Vicente, Kazuhiko Nakagawa, Sarah B. Goldberg, Myung-Ju Ahn, U. Scheuring, Scott J. Antonia, Ki Hyeong Lee, Byoung Chul Cho, Manuel Cobo Dols, F. Liu, Vladimir Moiseyenko, Naiyer A. Rizvi, Alexander Luft, Alexey Smolin, Solange Peters, Edward J. Kim, Delyth Clemett, P. Thiyagarajah, Rajiv Raja
Publikováno v:
Cancer Research. 79:CT074-CT074
Background High TMB is predictive of PFS benefit with anti-PD-(L)1 ± anti-CTLA-4 therapy in mNSCLC. Preliminary results from MYSTIC (NCT02453282), an open-label, Phase III trial of first-line durvalumab (D; anti-PD-L1), ± tremelimumab (T; anti-CTLA